Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

trategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the SEC. For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2008 filed with the SEC on Form 10-K, and our quarterly reports for the first, second and third quarters of 2009 filed with the SEC on Form 10-Q.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... 2015 Bionomics Limited (ASX:BNO, ADR:BMICY) is to ... BNC105 in patients with metastatic renal cancer at the ... . The data will be presented by Dr. ... Comprehensive Cancer Center in California ... data identifies Ferritin and IL-8 as two baseline biomarkers ...
(Date:2/27/2015)... , Feb. 27, 2015   PureTech , ... inventing and commercializing disruptive products and technologies in the ... Viehbacher , former CEO and Member of the Board ... "It,s has been a pleasure to ... excited that we will be working together more closely ...
(Date:2/26/2015)... Synageva BioPharma Corp. (NASDAQ: GEVA ... rare disorders, today reported 2014 full year financial ... and financial guidance.  Synageva,s management team will host ... to review the financial results and provide a ... by telephone, please dial (877) 445-4603 for U.S. ...
(Date:2/26/2015)... Woodbridge, NJ (PRWEB) February 26, 2015 ... and its affiliated companies, Wilentz, Goldman & ... in a trade secrets lawsuit against Genewiz Inc. in ... illegally obtained and utilized GenScript’s trade secrets, and that ... The court entered an order denying motions for ...
Breaking Biology Technology:New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 2Wilentz Client GenScript Awarded $10 Million in Trade Secrets Case Against Genewiz 3
... 29 Core Informatics announces,that it has delivered ... BioRelix Pharmaceuticals of New Haven, CT. BioRelix, which ... to establish a,strong data management infrastructure from the ... marketplace, BioRelix choose the Core LIMS., "After ...
... REDWOOD CITY, Calif., April 29 Genomic,Health, Inc. (Nasdaq: ... call and webcast on Tuesday, May 6, 2008 at 4:30 ... The call and,webcast will follow the release of the first ... To access the live conference call on May 6 at ...
... the,international life sciences investment group, today announced the,appointment ... based at the Company,s,offices in Waltham, MA, USA ... efforts in growth equity, which will include expansion ... and life,science companies. Abingworth plans to invest from ...
Cached Biology Technology:Core Informatics Delivers Enterprise Core LIMS Installation to BioRelix Pharmaceuticals 2Genomic Health to Announce First Quarter 2008 Financial Results and Host Conference Call on Tuesday, May 6, 2008 2Abingworth Appoints David Mayer as Partner 2
(Date:2/5/2015)... 2015   Epic Sciences , a precision diagnostics company ... Murali Prahalad , Ph.D., president and CEO, is scheduled ... (PMWC) 2015: Silicon Valley, which is taking place at the ... on January 26-28, 2015. Dr. Prahalad ... Biomarkers." Last year, Epic Sciences was a finalist in the ...
(Date:2/5/2015)... Jan. 28, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... RedChip Global Online CEO Conference on January 29 th ... Gino Pereira , CEO of NXT-ID will present and ... the Wocket smart wallet and its full suite of ...
(Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/4trb7t/biometrics_a ) has announced the addition ... report to their offering. , The primary ... is who she/he is claiming to be, and for this ... physical characteristics, such as fingerprint, hand or palm print, iris, ...
Breaking Biology News(10 mins):Epic Sciences to Present at Personalized Medicine World Conference 2015 on the Use of Circulating Tumor Cells as Cancer Biomarkers 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 2CEO of NXT-ID, Inc. to Discuss Company's Biometric Technologies at RedChip Online Conference January 29th 3Biometrics - A Global Market Overview 2Biometrics - A Global Market Overview 3
... a potential national health emergency, scientists have developed a ... future course of an avian influenza pandemic, given today's ... of scientists from Los Alamos National Laboratory in New ... Cancer Research Center in Seattle, is presented in the ...
... bonefish catch is always gratifying for the avid angler, ... Island in December proved even more satisfying for the ... Unlimited (BTU) and the University of Miami Rosenstiel School ... record catch, representing the longest movement by a bonefish ...
... For ants it's a way of life! Scientists at the ... learn how to visually judge the height of horizontal barriers ... down. Tobias Seidl will be presenting his latest research findings ... on Tuesday 4th April. , Desert ants generally scurry around ...
Cached Biology News:Avian flu modeled on supercomputer, explores vaccine and isolation options for thwarting a pandemic 2Avian flu modeled on supercomputer, explores vaccine and isolation options for thwarting a pandemic 3Avian flu modeled on supercomputer, explores vaccine and isolation options for thwarting a pandemic 4Record bonefish 2
... antigen and antibody-based immunoaffinity matrices, such ... many times without compromising antigen-antibody reactivity, ... chaotropic agents has precluded the application ... The CHEMICON Re-Blot Plus Western ...
Applications: Western blotting ...
...
... Acridinium esters have moderate chemiluminescence efficiencies ... well understood. They have the added benefit ... contribute little to the background signal. This ... in high sensitivity immunoassay applications. These compounds ...
Biology Products: